Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    115

Stocks News & Analysis

stocks

Finding value in the Aussie mining sector

Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
stocks

Strong start to the year for cheap ASX share

Investors are ignoring a strong long-term outlook.
stocks

Are there signs of an AI bubble in Nvidia’s earnings?

Our view after third-quarter results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,800.4036.000.41%
CAC 407,959.6722.98-0.29%
DAX 4023,239.18147.310.64%
Dow JONES (US)46,548.50303.090.66%
FTSE 1009,534.914.80-0.05%
HKSE25,716.50496.481.97%
NASDAQ22,855.19582.102.61%
Nikkei 22548,625.881,198.06-2.40%
NZX 50 Index13,499.8580.450.60%
S&P 5006,708.89105.901.60%
S&P/ASX 2008,525.1033.400.39%
SSE Composite Index3,836.771.870.05%

Market Movers